- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00371826
SOCRATES: Steroid or Cyclosporine Removal After Transplantation Using Everolimus
A Prospective, Open-label, Controlled Multicenter Trial to Assess the Efficacy and Safety of an Induction Regimen of Cyclosporine Micro Emulsion, Enteric-coated Mycophenolate Sodium (EC-MPS) and Corticosteroids, Followed by Administration of Everolimus and Enteric-coated Mycophenolate Sodium (EC-MPS), With Either the Withdrawal of Cyclosporine Micro Emulsion or Corticosteroids in de Novo Kidney Transplant Recipients
Studienübersicht
Status
Bedingungen
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 4
Kontakte und Standorte
Studienorte
-
-
-
NSW, Australien
- Royal Prince Alfred Hospital
-
NSW, Australien
- Westmead Hospital
-
QLD, Australien
- Princess Alexandra Hospital
-
Sale, Australien
- Monash Medical Centre
-
Sale, Australien
- Queen Elizabeth Hospital
-
VIC, Australien
- Royal Melbourne Hospital
-
WA, Australien
- Sir Charles Gairdner Hospital
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion criteria
- Males and females aged 18-65 years inclusive.
- First time recipients of cadaveric, living unrelated or living related donor kidney transplants.
- Patients who are willing and able to participate in the study and from whom written informed consent has been obtained.
Exclusion criteria
- Patients who are recipients of multiple organ transplants, including more than one kidney, kidney and pancreas, or previous transplant with any organ other than kidney.
- Patients at high immunological risk of graft loss, indicated by peak PRA >50% or loss of a previous renal allograft within the first 6 months of transplantation due to acute rejection.
- Patients who have received an investigational drug within 4 weeks prior to the screening visit.
- Presence of any severe allergy or hypersensitivity to drugs similar to everolimus (e.g. antibiotics such as Clindamycin)
Other protocol-defined inclusion/exclusion criteria may applied
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Calcineurin Inhibitor (CNI) Withdrawal
Every randomized patient in this group received Day 1 - Day 14: cyclosporine as Calcineurin Inhibitor (CNI) 5 mg/kg twice daily (b.i.d.), dose adjusted to achieve C2 target of 1,500 ng/mL (range 1,400-1,600 ng/mL) + mycophenolate sodium (MPA)720 mg b.i.d. + methylprednisone/prednisone 500 mg intra-operatively, 250 mg on day 1, then 10-30 mg/day prednisone Day 15 - Day 60: everolimus 1.5 mg b.i.d. to achieve target 6-10 ng/mL + cyclosporine decrease dose as per protocol guideline + MPA 720 mg b.i.d. until everolimus trough >6 ng/mL, then MPA was stopped + prednisone 10-30mg/day Day 61 - Day 120: everolimus dose adjusted to achieve target 6-10 ng/mL + cyclosporine 25% dose reduction per fortnight, to be discontinued by day 120 as per protocol (or commence reduction by day 120 at discretion of investigator, to be completed within 2 months of commencement) + prednisone 10-30mg/day Day 121 - Month 36: everolimus dose adjusted to achieve target 8-12 ng/mL + prednisone 5-10 mg/day |
Andere Namen:
Andere Namen:
Andere Namen:
|
Experimental: Steroid Withdrawal
Every randomized patient in this group received Day 1 -14: cyclosporine 5 mg/kg b.i.d., dose adjusted to achieve C2 target as per protocol + mycophenolate sodium (MPA) 720 mg b.i.d. + methylprednisone/prednisone 500 mg intra-operatively, 250 mg on day 1, then 10-30 mg prednisone per day Day 15 - 60: everolimus 1.5 mg b.i.d. to achieve target 6-10 ng/mL + cyclosporine decrease dose as per protocol guideline + MPA 720 mg b.i.d. until everolimus trough >6 ng/mL, then MPA was stopped + prednisone 10-30mg per day Day 61 - 120: Everolimus dose adjusted + cyclosporine adjust dose according protocol guideline (or commence reduction by day 120 at discretion of Investigator, to be completed within 2 months of commencement) + gradual withdrawal of prednisone by 1 mg/week to be discontinued by Day 120. Day 121 - Month 36: At Day 121, Month 7 and Month 13 Everolimus dose was adjusted to achieve target 6-10 ng/mL + Cyclosporine adjust dose to achieve C2 target as per protocol |
Andere Namen:
Andere Namen:
Andere Namen:
|
Aktiver Komparator: CNI+MPA+ Steroid
Patients randomized to this group received: Day 1 - Month 36: cyclosporine 5 mg/kg b.i.d., dose adjusted to achieve the protocol defined C2 Targets + mycophenolate sodium 720mg b.i.d. + Methylprednisone/prednisone 500mg intra-operatively, 250mg on day 1, 10-30mg prednisone per day until month 12 (as per local practice), 5-10mg/day months 13-36. |
Andere Namen:
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Calculated Glomerular Filtration Rate (cGFR) After Kidney Transplant to Evaluate Kidney Function (12 Months Analysis)
Zeitfenster: At Month 12
|
The glomerular filtration rate (GFR) was calculated by the Nankivell formula: GFR = 6.7 / Scr + BW / 4 - Surea / 2-100 / (height)^ 2 + C where Scr is the serum creatinine concentration expressed in mmol/L, BW the body weight in kg, Surea the serum urea in mmol/L, height in m, and the constant C is 35 for male and 25 for female patients.
|
At Month 12
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Calculated Glomerular Filtration Rate (cGFR) After Kidney Transplant to Evaluate Kidney Function (36 Months Analysis)
Zeitfenster: At Month 24 and 36
|
The glomerular filtration rate (GFR) was calculated by the Nankivell formula: GFR = 6.7 / Scr + BW / 4 - Surea / 2-100 / (height)^ 2 + C where Scr is the serum creatinine concentration expressed in mmol/L, BW the body weight in kg, Surea the serum urea in mmol/L, height in m, and the constant C is 35 for male and 25 for female patients.
|
At Month 24 and 36
|
Number of Participants With Biopsy Proven Acute Rejection (BPAR) Per Treatment Group (12 Months Analysis)
Zeitfenster: At Month 12
|
A biopsy-proven acute rejection is defined as a biopsy graded IA, IB, IIA, IIB, or III as per Banff 97 classification.
|
At Month 12
|
Number of Participants With Biopsy Proven Acute Rejection (BPAR) Per Treatment Group (36 Months Analysis)
Zeitfenster: At Month 12, 24 and 36
|
A biopsy-proven acute rejection is defined as a biopsy graded IA, IB, IIA, IIB, or III as per Banff 97 classification.
|
At Month 12, 24 and 36
|
Number of Participants With Composite Endpoint of Treatment Failure (12 Months Analysis)
Zeitfenster: Month 12
|
Composite endpoint of treatment failure includes biopsy-proven acute rejection (BPAR), graft loss, death and loss-to-follow-up. A BPAR is defined as a biopsy graded IA, IB, IIA, IIB, or III as per Banff 97 classification. The allograft was presumed to be lost on the day the patient started dialysis and was not able to subsequently be removed from dialysis. If the patient underwent a graft nephrectomy, then the day of nephrectomy was the day of graft loss. |
Month 12
|
Number of Participants With Composite Endpoint of Treatment Failure (36 Months Analysis)
Zeitfenster: At Month 12, 24 and 36
|
Composite endpoint of treatment failure includes biopsy-proven acute rejection (BPAR), graft loss, death and loss-to-follow-up. A BPAR is defined as a biopsy graded IA, IB, IIA, IIB, or III as per Banff 97 classification. The allograft was presumed to be lost on the day the patient started dialysis and was not able to subsequently be removed from dialysis. If the patient underwent a graft nephrectomy, then the day of nephrectomy was the day of graft loss. |
At Month 12, 24 and 36
|
Number of Participants With Histological Evidence Chronic Allograft Nephropathy (CAN) (12 Months Analysis)
Zeitfenster: At Month 12
|
A per-protocol biopsy was performed at Baseline and Month 12 and read by an independent blinded pathologist in order to assess chronic allograft nephropathy. Chronic rejection is characterized by a slow progressive decline in renal function and is typically preceded by the histological picture of chronic allograft nephropathy. The presence of biopsy confirmed Grade I, II or III chronic allograft nephropathy by Banff 97 criteria was assessed on all optional biopsies obtained for clinical suspicion of chronic rejection. Data summarized by 3 categories. "Yes" - Patients with histological evidence of CAN ; "No" - Patients with histological evidence of CAN and "Not Done" - Central protocol defined kidney allograft biopsies were not done. |
At Month 12
|
Number of Participants With Histological Evidence Chronic Allograft Nephropathy (CAN) (36 Months Analysis)
Zeitfenster: At Month 36
|
Chronic rejection is characterized by a slow progressive decline in renal function and is typically preceded by the histological picture of chronic allograft nephropathy. The presence of biopsy confirmed Grade I, II or III chronic allograft nephropathy by Banff 97 criteria was assessed on all optional biopsies obtained for clinical suspicion of chronic rejection. Data summarized by 3 categories. "Yes" - Patients with histological evidence of CAN ; "No" - Patients with histological evidence of CAN and "Not Done" - Central protocol defined kidney allograft biopsies were not done. |
At Month 36
|
Number of Participants With Sub Clinical Acute Rejection (12 Months Analysis)
Zeitfenster: At Month 12
|
Based on Banff 97 criteria, sub clinical acute rejection can be: GRADE IA - Cases with significant interstitial infiltration (>25% of parenchyma affected) and foci of moderate tubulitis (>4 mononuclear cells/tubular cross section or group of 10 tubular cells). GRADE IB - Cases with significant interstitial infiltration (>25% of parenchyma affected) and foci of moderate tubulitis (>10 mononuclear cells/tubular cross section or group of 10 tubular cells). GRADE IIA - Cases with significant interstitial infiltration and mild to moderate intimal arteritis (v1). GRADE IIB - Cases with moderate to severe intimal arteritis comprising >25% of the luminal area (v2). GRADE III - Cases with "transmural" arteritis or fibrinoid change and necrosis of medial smooth muscle cells (v3). "Borderline" category is used when no intimal arteritis is present, but there are foci of mild tubulitis (1 to 4 mononuclear cells/tubular cross section). |
At Month 12
|
Number of Participants With Sub Clinical Acute Rejection (36 Months Analysis)
Zeitfenster: At Month 36
|
Based on Banff 97 criteria, sub clinical acute rejection can be: GRADE IA - Cases with significant interstitial infiltration (>25% of parenchyma affected) and foci of moderate tubulitis (>4 mononuclear cells/tubular cross section or group of 10 tubular cells). GRADE IB - Cases with significant interstitial infiltration (>25% of parenchyma affected) and foci of moderate tubulitis (>10 mononuclear cells/tubular cross section or group of 10 tubular cells). GRADE IIA - Cases with significant interstitial infiltration and mild to moderate intimal arteritis (v1). GRADE IIB - Cases with moderate to severe intimal arteritis comprising >25% of the luminal area (v2). GRADE III - Cases with "transmural" arteritis or fibrinoid change and necrosis of medial smooth muscle cells (v3). "Borderline' category is used when no intimal arteritis is present, but there are foci of mild tubulitis (1 to 4 mononuclear cells/tubular cross section). |
At Month 36
|
Mean Serum Creatinine (12 Months Analysis)
Zeitfenster: At Month 12
|
At Month 12
|
|
Mean Serum Creatinine (36 Months Analysis)
Zeitfenster: At Month 12, 18, 24 and 36
|
At Month 12, 18, 24 and 36
|
|
Creatinine Clearance (CrCl) Calculated by the Cockcroft-Gault Formula (12 Months Analysis)
Zeitfenster: At Month 12
|
Creatinine clearance were calculated according to the Cockcroft-Gault formula: CrCl (males) = (140-A) × BW/(72 × Cr) CrCl (females) = CrCl (males) × 0.85 where A is age [years], BW is body weight [kg], and Cr is the serum concentration of creatinine [mg/dL]. The Cockcroft-Gault formula estimates creatinine clearance based on serum creatinine level, body weight, and age. |
At Month 12
|
Creatinine Clearance Calculated by the Cockcroft-Gault Formula (36 Months Analysis)
Zeitfenster: At Month 12, 24 and 36
|
Creatinine clearance were calculated according to the Cockcroft-Gault formula: CrCl (males) = (140-A) × BW/(72 × Cr) CrCl (females) = CrCl (males) × 0.85 where A is age [years], BW is body weight [kg], and Cr is the serum concentration of creatinine [mg/dL]. The Cockcroft-Gault formula estimates creatinine clearance based on serum creatinine level, body weight, and age. |
At Month 12, 24 and 36
|
Mean Urine Albumin/Creatinine Ratio (ACR) as Measurement of Proteinuria (12 Months Analysis)
Zeitfenster: At Month 12
|
Proteinuria is measured by spot morning urine Albumin/Creatinine Ratio [ACR].
When the ACR is more than or equal to 30 mg/mmol then it is known as proteinuria.
|
At Month 12
|
Mean Urine Albumin/Creatinine Ratio [ACR] as Measurement of Proteinuria (36 Months Analysis)
Zeitfenster: At Month 12, 18, 24 and 36
|
Proteinuria is measured by spot morning urine Albumin/Creatinine Ratio [ACR].
When the ACR is more than or equal to 30 mg/mmol then it is known as proteinuria.
|
At Month 12, 18, 24 and 36
|
Number of Participants With Post Transplant Diabetes Mellitus (PTDM) and Impaired Fasting Glucose (12 Months Analysis)
Zeitfenster: At Month 12
|
The symptoms of post transplant diabetes mellitus (PTDM) and impaired fasting glucose are defined as any of the following conditions:
|
At Month 12
|
Number of Participants With New Onset Diabetes Mellitus After Transplantation (NODAT) and Impaired Fasting Glucose (36 Months Analysis)
Zeitfenster: At Month 36
|
The symptoms of new onset diabetes mellitus after transplantation (NODAT) and impaired fasting glucose are defined as any of the following conditions:
|
At Month 36
|
Number of Participants With Notable Abnormal Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) as Measurement of Effect of Treatment on Cardiovascular Health (12 Months Analysis)
Zeitfenster: Baseline, Overall post-baseline up to 12 month
|
Notable abnormal systolic blood pressure is defined as :
Notable abnormal diastolic blood pressure is defined as :
|
Baseline, Overall post-baseline up to 12 month
|
Number of Participants With Notable Abnormal Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) as Measurement of Effect of Treatment on Cardiovascular Health (36 Months Analysis)
Zeitfenster: Baseline, Overall post baseline up to Month 36
|
Notable abnormal systolic blood pressure is defined as :
Notable abnormal diastolic blood pressure is defined as :
|
Baseline, Overall post baseline up to Month 36
|
Number of Participants With Erythropoietin Usage (12 Months Analysis)
Zeitfenster: Month 12
|
Month 12
|
|
Number of Participants With Erythropoietin Usage (36 Months Analysis)
Zeitfenster: Month 36
|
Month 36
|
|
Mean Short-form 36 Health Survey (SF-36) Score as a Measure of Quality of Life Assessment (12 Months Analysis)
Zeitfenster: At Month 12
|
SF-36 measures impact of disease on overall quality of life (QoL). 36-item survey has 8 subscales. The 8 subscales are: Physical functioning (PF), Role-physical (RP), Bodily pain (BP), General health (GH), Vitality (VT), Social functioning (SF), Role-emotional (RE) and Mental health (MH). Score for eash sub-scale has been standardized with the use of norm-based methods based on assessment of the general U.S. population free of chronic conditions. Scores range from 1-100 with a mean=50 and a standard deviation=10. A higher score indicates less impact on QoL. |
At Month 12
|
Mean Short-form 36 Health Survey (SF-36) Score as a Measure of Quality of Life Assessment (36 Months Analysis)
Zeitfenster: At Month 24
|
SF-36 measures impact of disease on overall quality of life (QoL). 36-item survey has 8 subscales. The 8 subscales are : Physical functioning (PF), Role-physical (RP), Bodily pain (BP), General health (GH), Vitality (VT), Social functioning (SF), Role-emotional (RE) and Mental health (MH). Score for each sub-scale has been standardized with the use of norm-based methods based on assessment of the general U.S. population free of chronic conditions. Scores range from 1-100 with a mean=50 and a standard deviation=10. A higher score indicates less impact on QoL. |
At Month 24
|
Number of Participants Hospitalized for Reasons Other Than Primary Transplantation (12 Months Analysis)
Zeitfenster: Month 12
|
This analysis is reporting number of participants hospitalized for reasons (such as acute rejection, infection, gastrointestinal (GI) events, cardiovascular event, metabolic disorder and Other) other than primary transplantation.
|
Month 12
|
Number of Participants Hospitalized for Reasons Other Than Primary Transplantation (36 Months Analysis)
Zeitfenster: Month 36
|
This analysis is reporting number of participants hospitalized for reasons (such as acute rejection, infection, gastrointestinal (GI) events, cardiovascular event, metabolic disorder and Other) other than primary transplantation.
|
Month 36
|
Number of Participants With Employment Status (12 Months Analysis)
Zeitfenster: At screening (at day 0 +/- 7 days ), At Month 12
|
The various employment status reported are:
|
At screening (at day 0 +/- 7 days ), At Month 12
|
Number of Participants With Employment Status (36 Months Analysis)
Zeitfenster: At screening (at day 0 +/- 7 days ), At Month 36
|
The various employment status reported are:
|
At screening (at day 0 +/- 7 days ), At Month 36
|
Number of Participants With Wound Problems(12 Months Analysis)
Zeitfenster: At Month 12
|
Patients with any wound healing problem such as infection related to kidney surgery, dehiscence, lymphocele, hernia, seroma, hematoma, ureteral anastomotic complication and other were reported in this analysis.
|
At Month 12
|
Number of Participants With Any Wound Problems (36 Months Analysis)
Zeitfenster: At Month 12, 24 and 36
|
Patients with any wound healing problem such as infection related to kidney surgery, dehiscence, lymphocele, hernia, seroma, hematoma, ureteral anastomotic complication and other were reported in this analysis.
|
At Month 12, 24 and 36
|
Number of Participants With Notable Abnormalities in Total Cholesterol and Triglycerides as Measurement of Effect of Treatment on Cardiovascular Health (12 Months Analysis)
Zeitfenster: Overall post baseline up to month 12
|
Notable abnormal total cholesterol is defined as : High: >= 9.1 mmol/L , normal range is 0.00 - 5.17 mmol/L Notable abnormal triglycerides is defined as : High: >= 8.5 mmol/L, normal range is 0.30 - 2.00 mmol/L |
Overall post baseline up to month 12
|
Number of Participants With Notable Abnormalities in Total Cholesterol and Triglycerides as Measurement of Effect of Treatment on Cardiovascular Health (36 Months Analysis)
Zeitfenster: Overall Post Baseline up to month 36
|
Notable abnormal total cholesterol is defined as : High: >= 9.1 mmol/L , normal range is 0.00 - 5.17 mmol/L Notable abnormal triglycerides is defined as : High: >= 8.5 mmol/L, normal range is 0.30 - 2.00 mmol/L |
Overall Post Baseline up to month 36
|
Number of Participants With Antibody-mediated Rejection Per Treatment Group (12 Months Analysis)
Zeitfenster: At Month 12
|
At Month 12
|
|
Number of Participants With Antibody-mediated Rejection Per Treatment Group (36 Months Analysis)
Zeitfenster: At Month 12, 24 and 36
|
At Month 12, 24 and 36
|
|
Number of Participants With Biopsy Proven Acute Rejection (BPAR) Influenced by Demographic Characteristics and Morbidities (12 Months Analysis)
Zeitfenster: At Month 12
|
The influence of demographic characteristics and comorbidities on incidence of BPAR were analyzed in the following way: Demographic characteristics were age (<55 years, ≥55 years), Expanded criteria Donor (ECD) organ (donor age >60 years or donor non heart-beating and donor age >50), gender, living vs. deceased donor, Body Mass Index (BMI) classes (underweight <18.5, normal 18.5 - <25.0, overweight 25.0 - <30.0, obesity 30.0 and above), years on dialysis before transplantation (<1, 1-5, >5 years).
Comorbidities were diabetes, hypertension, cardiovascular diseases/events, nephrosclerosis, glomerulonephritis/glomerular disease, polycystic disease, and Cytomegalovirus status.
|
At Month 12
|
Number of Participants With Biopsy Proven Acute Rejection (BPAR) Influenced by Demographic Characteristics and Morbidities (36 Months Analysis)
Zeitfenster: At Month 36
|
The influence of demographic characteristics and comorbidities on incidence of BPAR were analyzed in the following way: Demographic characteristics were age (<55 years, ≥55 years), Expanded Criteria Donor [ECD] organ (donor age >60 years or donor non heart-beating and donor age >50), gender, living vs. deceased donor, Body Mass Index (BMI) classes (underweight <18.5, normal 18.5 - <25.0, overweight 25.0 - <30.0, obesity 30.0 and above), years on dialysis before transplantation (<1, 1-5, >5 years).
Comorbidities were diabetes, hypertension, cardiovascular diseases/events, nephrosclerosis, glomerulonephritis/glomerular disease, polycystic disease, and Cytomegalovirus status.
|
At Month 36
|
Number of Patient Survival and Graft Survival (12 Months Analysis)
Zeitfenster: At Month 12
|
At Month 12
|
|
Number of Patient Survival and Graft Survival (36 Months Analysis)
Zeitfenster: At Month 12, 24 and 36
|
At Month 12, 24 and 36
|
|
Change in Bone Mineral Density Between Week 2 and Month 24 (36 Months Analysis)
Zeitfenster: Week 2, Month 24
|
Measurements of bone mineral density (BMD) by Dual Energy X-ray Absorptiometry (DEXA) were done at Week 2 and Month 24.
Change in BMD between week 2 and Month 24 were done for neck of femur and lumbar spine.
|
Week 2, Month 24
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Physiologische Wirkungen von Arzneimitteln
- Molekulare Mechanismen der pharmakologischen Wirkung
- Antiinfektiva
- Enzym-Inhibitoren
- Entzündungshemmende Mittel
- Antirheumatika
- Antineoplastische Mittel
- Immunsuppressive Mittel
- Immunologische Faktoren
- Glukokortikoide
- Hormone
- Hormone, Hormonersatzstoffe und Hormonantagonisten
- Antineoplastische Mittel, hormonell
- Dermatologische Wirkstoffe
- Antibakterielle Mittel
- Antibiotika, antineoplastische
- Antimykotika
- Antituberkulöse Mittel
- Antibiotika, Antituberkulose
- Prednison
- Mycophenolsäure
- Everolimus
- Cyclosporin
- Cyclosporine
- Calcineurin-Inhibitoren
Andere Studien-ID-Nummern
- CRAD001A2421
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Renal Transplanted Recipients
-
Hangzhou Endonom Medtech Co., Ltd.UnbekanntGuos viszerale Arterienrekonstruktion: Die erste Studie am Menschen zum WeFlow-JAAA-StentgraftsystemJuxta Renal Abdominal Aortenaneurysma ohne RupturChina
-
Saint-Joseph UniversityBeendet
-
Mayo ClinicNoch keine RekrutierungChronischer Kopfschmerz | Nussknacker-Syndrom, Nieren | Nussknacker-Phänomen, RenalVereinigte Staaten
-
Bradley A. McGregor, MDBristol-Myers Squibb; ExelixisRekrutierungNierenzellkarzinom | Chromophobes Nierenzellkarzinom | Papilläres Nierenzellkarzinom | Nicht klassifiziertes Nierenzellkarzinom | Collecting Duct Renal Cell Carcinoma | Translokation Nierenzellkarzinom | Nicht resezierbares fortgeschrittenes Nierenzellkarzinom | Metastasierendes Ncc-NierenzellkarzinomVereinigte Staaten
-
Leiden University Medical CenterRadboud University Medical Center; Health Holland; Dutch Kidney FoundationAbgeschlossenStörungen des Glukosestoffwechsels | Nierenerkrankungen | Diabetes Mellitus | Diabetische Nephropathien | Albuminurie | Mikroalbuminurie | Typ 2 Diabetes mellitus | Diabetische Nephropathie Typ 2 | Diabetische Komplikationen Renal | Süd asiatischNiederlande
-
Memorial Sloan Kettering Cancer CenterAktiv, nicht rekrutierendChromophobes Nierenzellkarzinom | Papilläres Nierenzellkarzinom | Nicht klassifiziertes Nierenzellkarzinom | Fortgeschrittenes oder metastasiertes nicht-klarzelliges Nierenzellkarzinom | Fumarathydratase-defizientes Nierenzellkarzinom | Succinat-Dehydrogenase-defizientes Nierenzellkarzinom | Collecting Duct Renal Cell CarcinomaVereinigte Staaten
-
Steno Diabetes Center CopenhagenKing's College London; Juvenile Diabetes Research Foundation; Glostrup University...Noch keine RekrutierungHypoxie | Diabetes mellitus, Typ 1 | Diabetische Nephropathien | Albuminurie | Nephropathie | Diabetische Komplikationen Renal | Diabetische Komplikationen Herz-KreislaufDänemark
Klinische Studien zur Everolimus (RAD001)
-
Novartis PharmaceuticalsAbgeschlossenLymphangioleiomyomatose (LAM) | Tuberöse Sklerose-Komplex (TSC)Vereinigte Staaten, Vereinigtes Königreich, Deutschland, Italien, Russische Föderation, Niederlande, Japan, Kanada, Polen, Frankreich, Spanien
-
Children's Hospital Medical Center, CincinnatiNovartisAbgeschlossenTuberöse Sklerose | AngiolipomVereinigte Staaten
-
Novartis PharmaceuticalsAbgeschlossenMetastasiertes Nierenzellkarzinom (mRCC)Deutschland
-
University of Alabama at BirminghamNational Cancer Institute (NCI); Children's Hospital of Philadelphia; Washington... und andere MitarbeiterAbgeschlossen
-
Novartis PharmaceuticalsAbgeschlossen
-
Guangdong Provincial People's HospitalNovartisUnbekanntNeuroendokrine Tumoren | Karzinoider TumorChina
-
University of ChicagoNovartis PharmaceuticalsBeendetNicht-kleinzelligem LungenkrebsVereinigte Staaten
-
Novartis PharmaceuticalsAbgeschlossenMetastasierendes NierenzellkarzinomChina
-
Novartis PharmaceuticalsBeendetPlexiformes Neurofibrom im Zusammenhang mit Neurofibromatose Typ 1Israel
-
Bayside HealthUnbekanntAkute myeloische LeukämieAustralien